Alpha Cognition (NASDAQ:ACOG) Announces Quarterly Earnings Results

Key Points

• Alpha Cognition missed quarterly earnings expectations, reporting a loss of $0.40 per share versus the consensus estimate of a $0.39 loss. The company posted a negative net margin of 232.23% and negative return on equity of 58.35%.
• ZUNVEYL revenue increased 71% sequentially to approximately $6 million, supported by growing prescriber and nursing-home adoption and strong repeat utilization. Management also reported positive BEACON findings and expects CONVERGE data in Q3 2026.
• Payer and formulary expansion remains a key challenge, with coverage at about 74% and limited formulary wins in the quarter. Alpha Cognition lowered its 2026 operating-expense outlook to $50 million–$54 million, ended Q2 with $41.4 million in cash, and maintained its goal of operating profitability in 2027.

Alpha Cognition (NASDAQ:ACOG - Get Free Report) posted its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01), Zacks reports. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%.

Here are the key takeaways from Alpha Cognition's conference call:

• ZUNVEYL net product revenue rose 71% sequentially to approximately $6 million in Q2 2026, with demand increasing each month and June marking the strongest month to date.
• Commercial adoption continued to deepen, with 1,347 active prescribers, 1,095 nursing homes placing prescriptions, and repeat utilization from approximately 76% of writers and 81% of prescribing homes.
• Management highlighted positive BEACON findings across cognition, neuropsychiatric symptoms, activities of daily living, and polypharmacy, while CONVERGE data is expected in Q3 2026 and RESOLVE remains on track to complete in Q2 2027.
• Payer and formulary expansion remains the largest near-term constraint; broad activation has been slower than expected, with coverage holding at roughly 74% and no significant formulary wins reported in Q2.
• The company reduced 2026 operating-expense guidance to $50 million-$54 million from $54 million-$58 million, ended Q2 with $41.4 million in cash, and reiterated its target of reaching operating profitability in 2027.

Alpha Cognition Stock Performance

Shares of NASDAQ:ACOG traded down $0.32 during midday trading on Thursday, hitting $8.63. The company's stock had a trading volume of 200,919 shares, compared to its average volume of 64,023. The stock's 50 day simple moving average is $7.63 and its 200 day simple moving average is $6.49. The stock has a market capitalization of $187.88 million, a price-to-earnings ratio of -6.39 and a beta of 2.31. Alpha Cognition has a fifty-two week low of $4.50 and a fifty-two week high of $10.00.

Institutional Investors Weigh In On Alpha Cognition

Several hedge funds have recently modified their holdings of ACOG. Ikarian Capital LLC boosted its position in shares of Alpha Cognition by 11.6% in the fourth quarter. Ikarian Capital LLC now owns 1,056,259 shares of the company's stock valued at $6,866,000 after acquiring an additional 110,000 shares during the period. Sphera Funds Management LTD. increased its position in Alpha Cognition by 67.6% during the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company's stock worth $3,690,000 after acquiring an additional 228,864 shares during the period. Opaleye Management Inc. increased its position in Alpha Cognition by 1,698.5% during the fourth quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company's stock worth $13,460,000 after acquiring an additional 1,955,642 shares during the period. Cantor Fitzgerald L. P. acquired a new position in Alpha Cognition during the 4th quarter valued at $1,062,000. Finally, AWM Investment Company Inc. raised its stake in Alpha Cognition by 52.6% during the 4th quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company's stock valued at $10,869,000 after purchasing an additional 576,516 shares during the last quarter.

Wall Street Analyst Weigh In

ACOG has been the topic of a number of analyst reports. Maxim Group started coverage on Alpha Cognition in a report on Friday, May 29th. They set a "buy" rating and a $12.00 price objective on the stock. Craig Hallum initiated coverage on Alpha Cognition in a research report on Friday, April 17th. They set a "buy" rating and a $14.00 target price for the company. Raymond James Financial began coverage on Alpha Cognition in a report on Friday, July 10th. They set an "outperform" rating and a $20.00 price target on the stock. Wall Street Zen lowered shares of Alpha Cognition from a "hold" rating to a "sell" rating in a research report on Saturday, May 2nd. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Alpha Cognition in a research note on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Alpha Cognition currently has a consensus rating of "Buy" and a consensus price target of $16.00.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source